You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rapid Point-of-Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood

    SBC: ZYMERON CORP            Topic: NIAID

    TuberculosisTBis currently the leading infectious cause of death worldwideTB treatment includes multiple different combinations of antibioticsdosesand long time periodsThe current standard includes an intensive phase ofmonthsfollowed by a continuation phase of eitherormonthsHowevertreatment outcome can be poor due to drug drug interactionsimpaired medication adherencedrug absorption and metabolism ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. In Vivo Targeted Degradation of HIV Gag Polyprotein by Gag-PROTAC Reagents

    SBC: ZYMERON CORP            Topic: NIAID

    HIV disease continues to be a serious health issue for the whole worldCurrentlyantiretroviral therapyARTis a widely accepted treatment to HIV infected patientswhich reduces morbidity and mortality and the potential for HIV transmission by suppressing viral replicationHowevertreatment outcomes of ART are limited due to the high adherence requirement and occurrence of drug resistanceProteolysis targ ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. SBIR PHASE 1- TOPIC 394- COMBINATORY TREATMENT MODALITIES UTILIZING RADIATION TO LOCALLY ACTIVATE OR RELEASE SYSTEMICALLY DELIVERED THERAPEUTICS.

    SBC: ZYMERON CORP            Topic: NCI

    Photodynamic therapyPDTutilizes light beam to activate photosensitizers to produce cytotoxic reactive oxygen speciesROSand it has been proposed as a potent treatment to combine with Radiation TherapyRTespecially for the idea of using X ray beam to locally activate PDTXPDTMajority studies about XPDT have used nanoscintillators as the X ray transducer to activate photosensitizersHoweverthe materials ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 382- INTEGRATED IMAGING AND MOLECULAR ANALYSIS OF GLIOBLASTOMA USING SCOPE SEQ ON THE AIR FLOW

    SBC: CELL MICROSYSTEMS INC            Topic: NCI

    Combining both genomic analysis and highEresolution imaging on a cellEbyEcell basis typically relies on customized technology which often requires significant expertise and capital costCell MicrosystemsInchas partnered with Peter SimsPhD of Columbia University to commercialize a novel workflow for integrated imaging and sample preparation for single cell transcriptomic analysisDrSims workflowSingl ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. An integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings.

    SBC: CERTIRX CORPORATION            Topic: NIDA

    Under the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop an integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a fixed-dose combination therapy for the treatment of chronic musculoskeletal pain

    SBC: NeuroCycle Therapeutics, Inc.            Topic: NIAMS

    PROJECT SUMMARY Non steroidal anti inflammatory drugsNSAIDsare a first line pharmacologic pain therapy for chronic musculoskeletal painand rheumatoid arthritisRAand moderate to severe osteoarthritisOAspecificallyHoweverinsufficient pain relief by NSAID monotherapy has encouraged the use of combination therapyCombinations of NSAIDs plus weak opioids are widely used although objective evidence for e ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding

    SBC: Dignify Therapeutics LLC            Topic: 105

    PROJECT SUMMARYABSTRACTSpinal cord injurySCIaffects an estimatedAmericansDamage to nerves in the spinal cord can result in a loss of voluntary control over bladder and bowel function that often produces both incontinence and retention of urine and stools in the same patientThe standard of care for urine retention is bladder catheterization to void urinewhich may produce urinary tract infectionsUTI ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain

    SBC: AFFINERGY, LLC            Topic: NIDA

    SUMMARY ABSTRACT Chronicnon cancer pain is a significant unmet health need worldwideThe prevalence of chronic pain among adults in the United States has been estimated at betweenandThe personal toll of living with chronic pain is immenseand the economic impact can be devastatingOne of the most widely used treatments for chronic pain is opioid analgesicsWhile the appropriate use of opioids can be a ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Developing novel inhibitors of the gut microbiome to modulate drug metabolism

    SBC: SYMBERIX, INC.            Topic: 100

    The long term objective of this project is a therapeutic adjunct to prevent adverse gastrointestinal eventsincluding life threatening diarrheaassociated with Ofevand Stivargaused to treat idiopathic pulmonary fibrosis and metastatic colorectal cancerrespectivelyAdverse GI events associated with both drugs is a major reason for reducingpostponingor stopping treatmentthus compromising efficacyOne fu ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government